Various Hepatic diseases

Reading File

Asking for Preferences

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Loading Image

Reading File

Loading Image

Reading File

I now have excellent content from multiple authoritative textbooks. Let me compile this into a comprehensive, well-structured overview.

Hepatic Diseases - Comprehensive Overview (Medical Student Edition)

Sources: Robbins & Kumar Basic Pathology, Schwartz's Principles of Surgery, Yamada's Textbook of Gastroenterology, Textbook of Family Medicine

Classification of Hepatic Diseases

Hepatic diseases are broadly grouped into:

Category	Examples
Infectious / Viral	Hepatitis A, B, C, D, E
Toxic / Drug-induced	Alcoholic liver disease, drug-induced hepatitis
Metabolic / Fatty Liver	NAFLD, NASH
Chronic / End-stage	Cirrhosis, portal hypertension
Acute Failure	Acute liver failure, acute-on-chronic failure
Neoplastic	Hepatocellular carcinoma (HCC)
Genetic / Metabolic	Hemochromatosis, Wilson's disease, α1-AT deficiency
Autoimmune	Autoimmune hepatitis, primary biliary cholangitis
Vascular	Budd-Chiari syndrome, hepatorenal syndrome

1. Acute Liver Failure (ALF)

Definition: Acute liver illness producing hepatic encephalopathy within 6 months of initial diagnosis, in the absence of prior liver disease.

Causes (US):

~50%: acetaminophen overdose (accidental or deliberate)
Remainder: autoimmune hepatitis, other drugs/toxins, acute hepatitis A and B
In Asia: hepatitis B and E predominate

Pathology (Massive Hepatic Necrosis):

Liver is small and shrunken due to parenchymal loss
Large zones of destruction with occasional islands of regenerating hepatocytes
Minimal scarring (too acute)

Massive liver necrosis - (A) small bile-stained liver; (B) perivenular (zone 3) confluent necrosis from acetaminophen overdose

Massive hepatic necrosis: (A) Small, bile-stained shrunken liver. (B) Perivenular (zone 3) confluent necrosis - typical of acetaminophen overdose. - Robbins & Kumar Basic Pathology

Clinical Features:

Feature	Mechanism
Jaundice + cholestasis	Bilirubin retention
Hepatic encephalopathy	Elevated ammonia (fails urea cycle); cerebral edema
Asterixis ("liver flap")	Ammonia-mediated CNS impairment
Coagulopathy	Loss of hepatic synthesis of clotting factors; paradoxic DIC
Portal hypertension	Ascites, hepatic encephalopathy
Hepatorenal syndrome	Nitric oxide-mediated splanchnic vasodilation → renal hypoperfusion

2. Cirrhosis & Chronic Liver Failure

Definition: Diffuse transformation of the entire liver into regenerative parenchymal nodules surrounded by fibrous bands - the final common pathway of chronic hepatic insult.

Gross appearance of cirrhotic liver - nodular surface from chronic viral hepatitis

Cirrhotic liver from chronic viral hepatitis - note the broad scars separating bulging regenerative nodules. - Robbins & Kumar Basic Pathology

Cirrhosis - gross laparoscopic view (top) and histology with fibrous bands (bottom)

Cirrhosis - laparoscopic gross view (top) and histology with regenerating nodules separated by bridging fibrosis (bottom). - Schwartz's Principles of Surgery

Etiology of Cirrhosis

Cause	Notes
Viral hepatitis (B, C, D)	Most common globally
Alcohol abuse	Alcoholic hepatitis → cirrhosis
NAFLD/NASH	Most common chronic liver disease worldwide
Autoimmune hepatitis	Responds well to steroids if caught early
Hemochromatosis	Iron overload
Wilson's disease	Copper overload
α1-Antitrypsin deficiency	Genetic; causes lung + liver disease
Primary biliary cirrhosis	Autoimmune bile duct destruction
Budd-Chiari syndrome	Hepatic vein outflow obstruction
Drugs/toxins	Methotrexate, amiodarone, etc.
Cryptogenic	~30% (many are unrecognized NASH)

Morphologic Types

Micronodular: Thick regular septa, uniform small nodules (typical of alcohol)
Macronodular: Variable-sized septa and nodules (typical of viral hepatitis)
Mixed: Conversion from micro to macronodular over time

Complications of Cirrhosis (End-Stage Liver Disease)

Portal Hypertension - the hallmark:

Mechanism: Increased vascular resistance at sinusoidal level (myofibroblast contraction + scarring) + increased portal blood flow (splanchnic vasodilation)
Results in esophagogastric varices (in ~40% of advanced disease) - risk of massive, fatal hematemesis
Ascites - transudate; serum-to-ascites albumin gradient (SAAG) ≥1.1 g/dL
Splenomegaly - can cause hypersplenism (thrombocytopenia, pancytopenia)
Caput medusae - recanalization of umbilical vein

Hepatic Encephalopathy: Ammonia accumulation → CNS impairment; asterixis

Hyperestrogenemia (in males): Palmar erythema, spider angiomas, gynecomastia, hypogonadism (from impaired estrogen metabolism)

Coagulopathy: ↓ clotting factors, easy bruising, bleeding

Hepatorenal Syndrome: Nitric oxide-mediated renal hypoperfusion in absence of intrinsic renal disease

ESLD Statistics:

5-year mortality: 50% (70% of deaths from liver failure)
US: ~30,000 deaths/year from cirrhosis
Additional 10,000-12,000 deaths/year from HCC

3. Viral Hepatitis

The hepatotropic viruses share the liver as their primary target. Key comparison table:

Feature	HAV	HBV	HCV	HDV	HEV
Genome	ssRNA	Partial dsDNA	ssRNA	Circular defective ssRNA	ssRNA
Transmission	Fecal-oral	Parenteral, sexual, perinatal	Parenteral	Parenteral	Fecal-oral
Incubation	2-6 wks	2-26 wks	4-26 wks	Same as HBV	4-5 wks
Chronic hepatitis	Never	5-10%	>80%	10% (coinfection); 90-100% (superinfection)	Immunocompromised only
Fulminant	~0.1%	0.1-0.5%	Rare	High with superinfection	Esp. in pregnancy
Carrier state	No	Yes	Yes	Yes	No

Source: Robbins & Kumar Basic Pathology, Table 14.2

Hepatitis A (HAV)

Picornavirus, nonenveloped ssRNA
Fecal-oral spread; shed in stool 2-3 weeks before and 1 week after onset of jaundice
Incubation: 2-6 weeks; endemic in areas of poor sanitation
Self-limited - no chronic hepatitis, no carrier state
Immunity follows infection: IgM (acute marker) then IgG (lifelong immunity)
Rarely fulminant (~0.1%)
Diagnosis: IgM anti-HAV (acute); IgG anti-HAV (past infection/immunity)

HAV serologic markers over time - fecal HAV, IgM, IgG, and total anti-HAV antibody curves

Hepatitis A serologic timeline - fecal HAV peaks during incubation; IgM rises during acute disease; IgG confers lifelong immunity. - Robbins & Kumar Basic Pathology

Hepatitis B (HBV)

Hepadnavirus, partially double-stranded circular DNA
Global burden: 2 billion ever infected; 250 million chronically infected; 75% of carriers in Asia/Pacific
Transmission varies by region: perinatal (high-prevalence areas), sexual/IVDU (low-prevalence)
Key viral antigens:
- HBsAg - surface antigen; first to appear; positivity >6 months = chronic
- HBcAg - core antigen (in hepatocytes); serum: anti-HBcAg IgM = acute infection
- HBeAg - secreted pre-core protein; marker of active replication and high infectivity
- HBV DNA - confirms active replication

Serology	Meaning
HBsAg (+), IgM anti-HBc (+)	Acute infection
HBsAg (+) >6 months	Chronic infection
Anti-HBs (+), anti-HBc (+)	Recovered/immune
Anti-HBs (+) only	Vaccinated
Anti-HBc IgM (+), HBsAg (-)	Window period

Outcomes: Recovery (most adults), chronic hepatitis (5-10%), cirrhosis, HCC, fulminant (0.1-0.5%)
Risk of chronicity is inversely proportional to age: ~90% in neonates, 5-10% in adults
HBx protein implicated in HCC pathogenesis
Treatment: Nucleoside analogues (tenofovir, entecavir); interferon-alpha

Hepatitis C (HCV)

Flavivirus, ssRNA; most common cause of chronic liver disease in the US (historically)
Spread primarily parenteral (IVDU, transfusions pre-1992, intranasal cocaine)
>80% progress to chronic hepatitis - the highest chronicity of all hepatitis viruses
Silent progression over decades - often discovered incidentally
Leading indication for liver transplant in the US (now declining with DAA therapy)
Direct-acting antivirals (DAAs): >90% sustained virologic response (SVR); have transformed management
Genotype 1 most common in the US

Hepatitis D (HDV)

Defective RNA virus - requires HBsAg coat to infect (cannot infect without HBV)
Coinfection (simultaneous HBV + HDV): usually self-limited, 10% chronic
Superinfection (HDV in chronic HBV carrier): 90-100% chronic, severe disease

Hepatitis E (HEV)

ssRNA, fecal-oral transmission; similar to HAV epidemiologically
Self-limited in immunocompetent hosts
Notable exception: High mortality in pregnant women (up to 20% maternal mortality)
Can cause chronic hepatitis in immunocompromised patients

4. Alcoholic Liver Disease (ALD)

A spectrum of hepatic injury caused by chronic alcohol use:

Stage	Features
Hepatic steatosis	Fat accumulation in >5% of hepatocytes; reversible with abstinence
Alcoholic hepatitis	Hepatocyte necrosis, Mallory bodies (cytokeratin inclusions), neutrophil infiltration, perivenular inflammation; can be acute and severe
Alcoholic cirrhosis	Irreversible fibrosis; micronodular pattern typical

Key pathologic finding: Mallory-Denk bodies (eosinophilic cytoplasmic inclusions)
Acetaldehyde, oxidative stress, and cytokines (esp. TNF-α) drive injury
Folate deficiency contributes to disease progression
Abstinence can lead to regression of fibrosis (even established cirrhosis in some cases)
Lab findings: AST:ALT ratio >2:1 (almost classic for ALD); GGT elevated

5. Non-Alcoholic Fatty Liver Disease (NAFLD) / NASH

NAFLD spectrum:

Steatosis (simple fatty liver): ≥5% hepatocytes with fat; relatively benign
NASH (Non-alcoholic steatohepatitis): Steatosis + hepatocellular ballooning + inflammation - progressive form
Fibrosis → Cirrhosis: ~1 in 10 NASH patients progress to cirrhosis
NASH-associated HCC: Risk lower than HCV cirrhosis but rising due to sheer prevalence

NAFLD is now the most common chronic liver disease worldwide, driven by the obesity epidemic.

Associations: Obesity, type 2 diabetes, metabolic syndrome, dyslipidemia, insulin resistance

Diagnosis: Steatosis on imaging (US, MRI) or biopsy; NASH requires biopsy to confirm (steatosis + lobular inflammation + ballooning + exclusion of alcohol use)

Management: Weight loss, exercise, treatment of metabolic comorbidities; resmetirom (THR-β agonist) is a recently approved drug for NASH with fibrosis

Liver transplant relevance:

Leading and fastest-growing indication for liver transplant in the US
30% macrovesicular steatosis in donor liver increases risk of graft failure

6. Hepatocellular Carcinoma (HCC)

Epidemiology:

13th most common cancer in the US; 5th most common cause of cancer death globally
85% of cases in low-/middle-income countries (Eastern Asia, sub-Saharan Africa)
Most rapidly increasing neoplasm in the United States

Risk factors:

Cirrhosis of any cause is present in 70-90% of HCC cases
HBV + HCV account for 80% of HCC worldwide
Aflatoxin B1 (contaminated food, Africa/Asia)
NASH/NAFLD, alcoholic cirrhosis, diabetes (Western countries)
Hemochromatosis, Wilson's disease, α1-AT deficiency, porphyria cutanea tarda

Presentation:

Often asymptomatic early
Late: jaundice, hepatomegaly, ascites, peripheral edema, RUQ pain, variceal bleeding

Diagnosis:

AFP (alpha-fetoprotein) - elevated in many cases
Imaging: triphasic contrast CT or MRI - nodules >1 cm with "arterial enhancement + washout" = diagnostic without biopsy
Biopsy if imaging inconclusive

Staging: Barcelona Clinic Liver Cancer (BCLC) system - most widely used, only prospectively validated

Treatment:

Curative: Surgical resection (70% recurrence rate), liver transplantation (Milan criteria: single lesion <5 cm OR ≤3 lesions each <3 cm)
Locoregional: Radiofrequency ablation, transarterial chemoembolization (TACE)
Systemic: Sorafenib, atezolizumab + bevacizumab (first-line for advanced disease)

Prognosis:

5-year survival: 34% (confined to liver), 12% (regional LN involvement), <3% (metastatic)

7. Genetic/Metabolic Liver Diseases

Disease	Defect	Key Features
Hereditary Hemochromatosis	HFE gene mutation → iron overload	"Bronze diabetes" (skin pigmentation, cirrhosis, DM, cardiomyopathy, hypogonadism); Prussian blue stain for iron
Wilson's Disease	ATP7B mutation → copper accumulation	Young patient; Kayser-Fleischer rings (cornea), hepatitis/cirrhosis, neuropsychiatric symptoms; low ceruloplasmin
α1-Antitrypsin Deficiency	Misfolded AAT retained in ER	Liver disease (PAS+ diastase-resistant globules in hepatocytes) + emphysema
Primary Biliary Cholangitis (PBC)	Autoimmune destruction of intrahepatic bile ducts	Middle-aged women; pruritus, fatigue; anti-mitochondrial antibody (AMA) positive; ↑ ALP
Autoimmune Hepatitis	Autoimmune hepatocyte destruction	Females; ↑ IgG; anti-smooth muscle antibody (ASMA) or ANA; responds to corticosteroids

8. Vascular Hepatic Disorders

Condition	Mechanism	Key Features
Budd-Chiari Syndrome	Hepatic vein thrombosis	Painful hepatomegaly, ascites, acute liver failure; associated with hypercoagulable states, polycythemia vera, pregnancy
Congestive Hepatopathy	Right heart failure → hepatic venous congestion	"Nutmeg liver" (centrilobular congestion); ascites, ↑ transaminases
Hepatorenal Syndrome (HRS)	Functional renal failure in liver failure	No intrinsic renal disease; type 1 (acute, rapidly progressive), type 2 (slower); triggered by SBP, diuretics, GI bleed
Portal Vein Thrombosis	Thrombosis of portal vein	Variceal bleeding without cirrhosis; associated with prothrombotic states, abdominal sepsis

9. Drug-Induced Liver Injury (DILI)

One of the most common causes of acute liver failure
Patterns: Hepatocellular (↑ ALT >> ALP), Cholestatic (↑ ALP >> ALT), or Mixed
Key offenders:

Drug	Pattern	Notes
Acetaminophen	Hepatocellular (zone 3 necrosis)	Dose-dependent; antidote: N-acetylcysteine
Isoniazid (INH)	Hepatocellular	Idiosyncratic; serious in elderly
Amiodarone	Mixed/steatohepatitis	Phospholipidosis pattern
Methotrexate	Fibrosis/cirrhosis	Chronic use; cumulative dose
Statins	Hepatocellular (usually mild)	Rarely serious
Alcohol	Steatohepatitis	See ALD above

10. Key Lab Patterns (High-Yield Summary)

Pattern	Likely Cause
↑↑ AST, ALT (>1000 U/L)	Viral hepatitis, ischemic hepatitis, acetaminophen toxicity
AST:ALT >2:1	Alcoholic liver disease
↑ ALP >> ALT	Cholestatic disease (PBC, PSC, biliary obstruction)
↑ Bilirubin + ↑ PT/INR	Severe hepatic dysfunction
↓ Albumin + ↑ PT/INR	Chronic liver failure (poor synthetic function)
↑ AFP	HCC (also seen in acute hepatitis)

Summary: Key High-Yield Points

Cirrhosis = final common pathway of chronic liver injury; defined by nodules + fibrous bands throughout the liver
Portal hypertension causes the major complications: varices, ascites, encephalopathy, splenomegaly
HCV has the highest rate of chronicity (>80%); DAAs have revolutionized treatment
HBV risk of chronicity is inversely related to age (neonates: 90%, adults: 5-10%)
HAV and HEV are fecal-oral, never chronic in immunocompetent (HEV: dangerous in pregnancy)
NAFLD/NASH is now the most common chronic liver disease worldwide - driven by the obesity epidemic
HCC arises on a background of cirrhosis in 70-90% of cases; HBV + HCV account for 80% globally
Acetaminophen = leading cause of acute liver failure in the US; antidote is N-acetylcysteine
Wilson's disease = suspect in young patient with hepatitis + neuropsychiatric symptoms + low ceruloplasmin
MELD score (Model for End-Stage Liver Disease) is used to prioritize liver transplant allocation

Sources: Robbins & Kumar Basic Pathology, 10th ed. | Schwartz's Principles of Surgery, 11th ed. | Yamada's Textbook of Gastroenterology, 7th ed. | Textbook of Family Medicine, 9th ed. | Tietz Textbook of Laboratory Medicine, 7th ed.

This is a shared conversation. Sign in to Orris to start your own chat.